ZNTL offering history
Every offering-related filing in Zentalis Pharmaceuticals, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 542 filings back to Dec 19, 2017.
| Date | Filing | What it means | |
|---|---|---|---|
| Aug 14, 2026 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Aug 13, 2026 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Apr 4, 2025 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Mar 26, 2025 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Feb 29, 2024 | S-3ASR → | REGISTERED | Automatic shelf registration — effective immediately (large filers) |
| Jun 15, 2023 | FWP → | MARKETING | Free-writing prospectus — offering being marketed |
| Jun 15, 2023 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| May 16, 2022 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Apr 27, 2022 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Jun 30, 2021 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Jun 28, 2021 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| May 4, 2021 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| May 4, 2021 | RW → | WITHDRAWN | Registration withdrawn |
| May 4, 2021 | S-3ASR → | REGISTERED | Automatic shelf registration — effective immediately (large filers) |
| Jul 31, 2020 | 424B4 → | EXECUTED | Final prospectus — offering priced (typical for IPOs and marketed share deals) |
| Jul 29, 2020 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Jul 28, 2020 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Jul 27, 2020 | S-1 → | REGISTERED | S-1 registration — capacity to sell shares, not a sale yet |
| Apr 6, 2020 | 424B4 → | EXECUTED | Final prospectus — offering priced (typical for IPOs and marketed share deals) |
| Apr 2, 2020 | S-1MEF → | REGISTERED | S-1MEF registration — capacity to sell shares, not a sale yet |
| Apr 2, 2020 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Mar 31, 2020 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Mar 30, 2020 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Mar 6, 2020 | S-1 → | REGISTERED | S-1 registration — capacity to sell shares, not a sale yet |
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
ZNTL offering FAQ
When did ZNTL last execute an offering?
Per SEC filings, Zentalis Pharmaceuticals, Inc.'s most recent priced offering document is a 424B5 filed 2026-08-14. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did ZNTL last announce or register an offering?
The most recent registration is a S-3 filed 2025-03-26. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.